SONN Stock: Sonnet BioTherapeutics Holdings, Inc. Stock Price, Analysis & Insights
Get live sonn stock price $5.90, comprehensive Sonnet BioTherapeutics Holdings, Inc. stock analysis, charts, news, and expert forecast. Real-time sonn stock data and investment insights.
Company Overview
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Company Information
- CEO
- Raghu Rao
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
Contact Information
- Website
- https://www.sonnetbio.com
- Address
- 100 Overlook Center
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 39.49M market capitalization
- Trading Volume: 7.49M shares traded today
- Price Range: 52-week range of $1.08 - $19.30
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc. (SONN) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 39.49M, the company represents a significant player in its market. The stock is currently trading at $5.90 with a positivedaily change of 48.99%.
The company's 13 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.87, beta of 1.22, and 52-week price range from $1.08 to $19.30when evaluating investment opportunities.
Why Invest in Sonnet BioTherapeutics Holdings, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Raghu Rao
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.